Navigation Links
Rigel Announces Fourth Quarter and Year End 2007 Financial Results
Date:2/12/2008

s of $74.3 million, or $2.57 per share. This compares to revenues of $33.5 million and a net loss of $37.6 million, or $1.51 per share for the same period in 2006. The decrease in revenue is due to various milestone and upfront payments from Merck, Merck Serono and Pfizer recognized in 2006.

As of December 31, 2007, Rigel had cash, cash equivalents and available for sale securities of $108.3 million, compared with $112.5 million at September 30, 2007 and $104.5 million at December 31, 2006. During the first quarter of 2008, we completed a public offering in which we sold 5,000,000 shares of our common stock at a price of $27.00 per share. We received net proceeds of approximately $127.5 million after deducting underwriting discounts and commissions and offering expenses.

"The recent announcement of the results from our Phase 2 clinical trial in rheumatoid arthritis with our lead drug candidate, R788, has focused investors' interest in Rigel's R&D programs," said James M. Gower, Rigel's chairman and chief executive officer. "As a result of our recent financing, we are positioned to move R788 into advanced clinical studies while continuing development of new therapeutic opportunities in our pipeline."

About Rigel (http://www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our goal is to file one new investigational new drug application in a significant indication each year. Rigel has achieved this goal every year since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in seven strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product dev
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Rigel to Present at BIO Investor Forum 2007
2. Rigel to Present Research Programs at Scientific Conferences
3. Rigel Announces Pricing of Public Offering of Common Stock
4. Rigel to Present at BIO CEO & Investor Conference
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 ... consumers, are increasingly searching for food alternatives that ... nutritional benefits. The food ingredient market has numerous ... players such as Vital Force Technology (VFT). ... more than 4,000 energetic patterns, all tested to ...
(Date:7/31/2014)... 2014 Nearly 20,000 medical professionals and healthcare ... & Clinical Lab Expo in Chicago ... in diagnostic research and technology that will advance medicine ... As of Wednesday, July 30, more than 19,500 attendees ... Clinical Lab Expo, with more than 10,000 of these ...
(Date:7/31/2014)... ability to see through organs and even the entire ... as fine-grained cellular structures has been a long-time dream ... Press July 31st in the journal Cell ... methods for making opaque organs, bodies, and human tissue ... intact. The protocols could pave the way for a ...
(Date:7/31/2014)... SPRINGS, Colo. , July 31, 2014 /PRNewswire-USNewswire/ ... Grant awardee today with $25,000 to fund a ... Foundation,s inception in 2011, the gift was presented ... th Annual Meeting in Colorado ... who specialize in neurointerventional approaches to neurovascular conditions, ...
Breaking Biology Technology:Functional Ingredient Manufacturer – Vital Force Technology Infuses Raw Materials & Ingredients with Subtle Energy Formula 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 3See-through organs and bodies will accelerate biomedical discoveries 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3
... DirectorFAIRFAX, Va., Feb. 25 Edmond Scientific Company ... our team of Tony Mallia as Practice Director. ... bringing to bear his experience of enterprise integration in ... financial services sectors. The core goal of this methodology ...
... plastic surgeryMEDFORD, Mass., Feb. 25 Serica ... developing silk-based biomaterial platforms for tissue regeneration, ... from the U.S. Food and Drug Administration ... long term bioresorbable scaffold technology."We are delighted ...
... 25 Bio-Matrix Scientific Group,Inc. (OTC Bulletin Board: BMSN) ... created positions on its management team. Feng Lin, M.D., ... Laboratory/Scientific,Director and Marilyn Panahi is serving as Quality Assurance ... and Marilyn Panahi bring tremendous expertise to the,administrative operations ...
Cached Biology Technology:Edmond Scientific Company 'Spotlight on the Executive': 2Serica Technologies Receives FDA 510(k) Clearance for SeriScaffold(TM) Technology for Soft Tissue Repair 2Serica Technologies Receives FDA 510(k) Clearance for SeriScaffold(TM) Technology for Soft Tissue Repair 3Serica Technologies Receives FDA 510(k) Clearance for SeriScaffold(TM) Technology for Soft Tissue Repair 4Bio-Matrix Scientific Group Announces New Hires to Management Team 2
(Date:8/1/2014)... enormous opportunities for both biological and future clinical ... cells in the body, offering immense hope of ... kidney, liver and lung diseases and making damaged ... Prof. Jinhui Chen from Indiana University in USA ... myriad biological, ethical, legal, political, and financial challenges. ...
(Date:8/1/2014)... Colo., USA One of the most diverse families ... as Lucinidae (or lucinids) -- originated more than 400 ... and life habits like those of its modern members. ... the University of Hawaii, published online on 25 July ... through significant symbiotic relationships. , At is origin, the ...
(Date:8/1/2014)... -- LiveScan Service Provider Binary Biometrics is pleased to welcome Kevin ... will improve its mobile service capabilities and add more daily appointments, which will ... service several new cities such as, but not limited to, Daytona ... Deltona , Edgewater , Holly ... Beach , Oak Hill , Orange City ...
Breaking Biology News(10 mins):Symbiotic survival 2Symbiotic survival 3Symbiotic survival 4Symbiotic survival 5Symbiotic survival 6Symbiotic survival 7Symbiotic survival 8Symbiotic survival 9Symbiotic survival 10Symbiotic survival 11Symbiotic survival 12Symbiotic survival 13Symbiotic survival 14Binary Biometrics, Founded by James Timothy White, Expands Services to 13+ Locations With the Addition of Owner/Operator Kevin Morris 2Binary Biometrics, Founded by James Timothy White, Expands Services to 13+ Locations With the Addition of Owner/Operator Kevin Morris 3
... great at protecting leaves from being chomped by slugs, suggests ... . Although they lurk in the soil, they seem to ... the amount of damage slugs do to individual plants. ... 100 worst alien species in Europe and are considered a ...
... more than 13,000 men identified four new genetic variants ... most commonly diagnosed type in young men today. The ... 12 in Nature Genetics by researchers at ... of Pennsylvania . The discovery of these genetic ...
... anomalous pulmonary venous connection (TAPVC), one type of "blue ... occurs when pulmonary veins don,t connect normally to the ... oxygenated blood throughout the body, and TAPVC babies are ... , TAPVC is usually detected in newborns when babies ...
Cached Biology News:Penn Medicine researchers identify 4 new genetic risk factors for testicular cancer 2Penn Medicine researchers identify 4 new genetic risk factors for testicular cancer 3Mutation causing wrong-way plumbing explains 1 type of blue-baby syndrome 2
Certified U.S. origin. Bovine Serum:, *Certified U.S. origin. Available raw, nonsterile filtered, or sterile filtered. , , *Sterility tested , , *Low Hemoglobin levels , , *Mycoplasma testing upon...
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
No description available in Ensembl Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
... contains 4 deuterium atoms at the 9, 10, ... use as an internal standard for the quantification ... is produced by the lipoxygenation of linoleic acid ... detected in atherosclerotic plaques, as an esterified component ...
Biology Products: